Elicera Therapeutics AB (ELIC) AI Stock Analysis

• Market Cap: kr249.96M
• Dividend Yield: N/A
• Average Volume (3M): 134.24K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.15
• Revenue Growth: N/A
• EPS Growth: 52.96%
• Country: SE
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): <0.01
• Shares Outstanding: 48,535,545
• 10 Day Avg. Volume: 92,396
• 30 Day Avg. Volume: 134,243
• PEG Ratio: 0.08
• Price to Book (P/B): 2.54
• Price to Sales (P/S): 7.40
• P/FCF Ratio: -2.25
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -3.81
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: kr5.50 ▲(2.80% Upside)

The score is held down primarily by weak financial performance driven by large ongoing losses and negative free cash flow, despite a clean no-debt balance sheet. Technicals are also soft with the stock below key moving averages and a negative MACD, while valuation is difficult to support with a negative P/E and no dividend yield.

Positive Factors

Balance Sheet Strength

A debt-free balance sheet reduces financial risk and provides flexibility, allowing the company to focus on R&D and strategic growth without immediate financial pressure.

Improving Cash Burn

Improvement in cash burn indicates better financial management and operational efficiency, which is crucial for a biotech firm in the pre-commercialization phase.

Narrowing Losses

Narrowing losses suggest progress towards profitability, which is vital for long-term sustainability and investor confidence in a high-risk industry like biotechnology.

Negative Factors

Negative Profitability

Persistent negative profitability indicates ongoing challenges in achieving a sustainable business model, which can impact future funding and growth prospects.

Declining Revenue

Declining revenue reflects challenges in market penetration and product adoption, which are critical for long-term viability in the competitive biotech sector.

Negative Cash Flow

Negative cash flow highlights the company's reliance on external funding, posing a risk to operational continuity and strategic initiatives if funding becomes constrained.

Elicera Therapeutics AB Business Overview & Revenue Model

Company Description

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.

How the Company Makes Money

Elicera Therapeutics AB generates revenue primarily through research and development collaborations, licensing agreements, and potential milestone payments related to its proprietary technologies and therapeutic candidates. The company may also seek grants and funding from governmental or non-governmental entities to support its research initiatives. Elicera's revenue model is likely driven by strategic partnerships with larger pharmaceutical companies, which can provide upfront payments, research funding, and royalties on future sales if the therapies reach commercialization. Additionally, successful clinical trials and regulatory approvals could open avenues for direct sales or additional licensing deals.

Elicera Therapeutics AB Financial Statement Overview

Summary

Elicera Therapeutics AB faces significant challenges with profitability and cash generation, demonstrated by consistent losses and negative cash flow. Despite a strong equity position with no debt, the declining revenue and cash flow figures point to potential risks in financial sustainability.

Income Statement

Elicera Therapeutics AB shows a volatile revenue trend with a decline in revenue from 2023 to 2024. The company operates at a significant loss, demonstrated by negative EBIT and net income margins, indicating challenges in achieving profitability.

Balance Sheet

The company maintains a strong equity position with no debt, reflected in a low debt-to-equity ratio. However, declining equity and total assets indicate potential challenges in sustaining financial stability.

Cash Flow

Negative operating and free cash flow highlight cash management challenges. The significant drop in free cash flow growth from 2023 to 2024 raises concerns about the company's ability to generate cash from operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.79M	7.13M	11.23M	1.28M	587.00	0.00
Gross Profit	5.79M	7.13M	11.22M	1.28M	-11.19K	-11.78K
EBITDA	-13.24M	-16.82M	-17.09M	-19.43M	-13.11M	-2.82M
Net Income	-13.04M	-16.11M	-16.40M	-19.52M	-13.12M	-2.82M
Balance Sheet
Total Assets	37.30M	27.56M	30.18M	46.31M	54.74M	12.59M
Cash, Cash Equivalents and Short-Term Investments	34.92M	26.40M	29.38M	43.82M	52.39M	11.56M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	6.97M	6.79M	13.78M	13.51M	2.50M	2.35M
Stockholders Equity	30.33M	20.77M	16.40M	32.80M	52.24M	10.24M
Cash Flow
Free Cash Flow	-15.71M	-23.46M	-14.92M	-8.57M	-14.29M	-964.13K
Operating Cash Flow	-15.71M	-23.46M	-14.92M	-8.57M	-14.29M	-905.25K
Investing Cash Flow	1.00K	0.00	483.17K	0.00	-1.00K	-8.88K
Financing Cash Flow	20.00M	20.48M	0.00	0.00	55.12M	12.45M

Elicera Therapeutics AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.35
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ELIC, the sentiment is Negative. The current price of 5.35 is below the 20-day moving average (MA) of 5.65, below the 50-day MA of 5.72, and below the 200-day MA of 5.46, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 37.30 is Neutral, neither overbought nor oversold. The STOCH value of 27.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ELIC.

Elicera Therapeutics AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ELIC	47 Neutral	kr249.96M	-15.14	-48.30%	―	―	52.96%